All In Biotech

Drug Trial Radar · NCT05672576

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 451 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

451

Actual

Start

Jun 26, 2023

Primary completion

Dec 31, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Viatris Innovation GmbHIndustry
Sponsor type
Industry
First posted
Jan 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult patients with Systemic Lupus Erythematosus. Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already being administered. In this research study approximately 210 participants will receive cenerimod and approximately 210 participants will receive placebo for 12 months.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • CenerimodDrug

    Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.

  • PlaceboDrug

    Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Month 12 compared to baselineTime frame: At Month 12 compared to Day 1 (pre-dose baseline)

Locations

147 sites in 18 countries. Site status is shown where the registry gives one.

  • Tucson Clinical Research Institute, LLC

    Tucson, Arizona

  • UCSD Perlman Medical Offices

    La Jolla, California

  • Amicis Research Center

    Northridge, California

  • Hope Clinical Trials, Inc.

    Coral Gables, Florida

  • Vital Pharma Research

    Hialeah, Florida

  • Tectum Medical Research

    Hollywood, Florida

  • Alloy Clinical Research, LLC

    Kissimmee, Florida

  • Allied Biomedical Research Institute

    Miami, Florida

  • D&H National Research Centers INC

    Miami, Florida

  • Professional research Center INC

    Miami, Florida

  • San Marcus Research Clinic, Inc.

    Miami Lakes, Florida

  • Tandem Clinical Research

    Marrero, Louisiana

  • RB Wellness Clinic

    Las Vegas, Nevada

  • Columbia University Medical Center

    New York, New York

  • Precision Comprehensive Clinical Research Solutions

    Colleyville, Texas

  • Texas Arthritis Center

    El Paso, Texas

  • Northwest Houston Arthritis Center

    Houston, Texas

  • Biomedica Research Group

    Providencia, Chile

  • Sociedad Médica del Aparato Locomotor S. A.

    Providencia, Chile

  • Estudios G y C Ltda

    Santiago, Chile

  • Enroll SpA

    Santiago, Chile

  • Centro de Especialidades Medicas Vanguardia

    Temuco, Chile

  • Clinical Research Chile SpA

    Valdivia, Chile

  • Hospital San José de Victoria

    Victoria, Chile

  • iMedica s.r.o.

    Brno, Czechia

  • Institute of Rheumatology Prague

    Prague, Czechia

  • LTD "New Plasma Clinic"

    Batumi, Georgia

  • Institute of Clinical Cardiology, Ltd

    Tbilisi, Georgia

  • LTD "Tbilisi Central Hospital"

    Tbilisi, Georgia

  • National Institute of Endocrinology Ltd.

    Tbilisi, Georgia

  • Tbilisi Heart and Vascular Clinic Ltd.

    Tbilisi, Georgia

  • Aversi Clinic LTD

    Tbilisi, Georgia

  • Medi Club Georgia Ltd.

    Tbilisi, Georgia

  • Tbilisi Institute of Medicine

    Tbilisi, Georgia

  • JSC Jerarsi Clinic

    Tbilisi, Georgia

  • Ltd. Mtskheta Street Clinic

    Tbilisi, Georgia

  • The First Medical Center Ltd.

    Tbilisi, Georgia

  • Caucasus Medical Centre

    Tbilisi, Georgia

  • LLC "Innova"

    Tbilisi, Georgia

  • LLC Raymann

    Tbilisi, Georgia

Showing 40 of 147 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.